112 related articles for article (PubMed ID: 15719330)
1. Cost-effectiveness analysis of a kidney and cardiovascular disease treatment program in an Australian Aboriginal population.
Baker PR; Hoy WE; Thomas RE
Adv Chronic Kidney Dis; 2005 Jan; 12(1):22-31. PubMed ID: 15719330
[TBL] [Abstract][Full Text] [Related]
2. Reduction in natural death and renal failure from a systematic screening and treatment program in an Australian Aboriginal community.
Hoy WE; Wang Z; Baker PR; Kelly AM
Kidney Int Suppl; 2003 Feb; (83):S66-73. PubMed ID: 12864878
[TBL] [Abstract][Full Text] [Related]
3. Reducing premature death and renal failure in Australian aboriginals. A community-based cardiovascular and renal protective program.
Hoy WE; Baker PR; Kelly AM; Wang Z
Med J Aust; 2000 May; 172(10):473-8. PubMed ID: 10901769
[TBL] [Abstract][Full Text] [Related]
4. Secondary prevention of renal and cardiovascular disease: results of a renal and cardiovascular treatment program in an Australian aboriginal community.
Hoy WE; Wang Z; Baker PR; Kelly AM
J Am Soc Nephrol; 2003 Jul; 14(7 Suppl 2):S178-85. PubMed ID: 12819325
[TBL] [Abstract][Full Text] [Related]
5. Stemming the tide: reducing cardiovascular disease and renal failure in Australian Aborigines.
Hoy W; Kelly A; Jacups S; McKendry K; Baker P; MacDonald S; Wang Z; Punguatji N; Kerinauia J; Tipiloura E; Tipiloura E; Harrison C
Aust N Z J Med; 1999 Jun; 29(3):480-3. PubMed ID: 10868523
[TBL] [Abstract][Full Text] [Related]
6. Screen-and-treat strategies for albuminuria to prevent cardiovascular and renal disease: cost-effectiveness of nationwide and targeted interventions based on analysis of cohort data from the Netherlands.
Boersma C; Gansevoort RT; Pechlivanoglou P; Visser ST; van Toly FF; de Jong-van den Berg LT; de Jong PE; Postma MJ;
Clin Ther; 2010 Jun; 32(6):1103-21. PubMed ID: 20637965
[TBL] [Abstract][Full Text] [Related]
7. Albuminuria in a remote South Australian Aboriginal community: results of a community-based screening program for renal disease.
Shephard MD; Allen GG; Barratt LJ; Barbara JA; Paizis K; McLeod G; Brown M; Vanajek A
Rural Remote Health; 2003; 3(1):156. PubMed ID: 15877493
[TBL] [Abstract][Full Text] [Related]
8. Cost effectiveness of ramipril treatment for cardiovascular risk reduction.
Malik IS; Bhatia VK; Kooner JS
Heart; 2001 May; 85(5):539-43. PubMed ID: 11303006
[TBL] [Abstract][Full Text] [Related]
9. Screening for proteinuria in US adults: a cost-effectiveness analysis.
Boulware LE; Jaar BG; Tarver-Carr ME; Brancati FL; Powe NR
JAMA; 2003 Dec; 290(23):3101-14. PubMed ID: 14679273
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of screening for albuminuria with subsequent fosinopril treatment to prevent cardiovascular events: A pharmacoeconomic analysis linked to the prevention of renal and vascular endstage disease (PREVEND) study and the prevention of renal and vascular endstage disease intervention trial (PREVEND IT).
Atthobari J; Asselbergs FW; Boersma C; de Vries R; Hillege HL; van Gilst WH; Gansevoort RT; de Jong PE; de Jong-van den Berg LT; Postma MJ;
Clin Ther; 2006 Mar; 28(3):432-44. PubMed ID: 16750458
[TBL] [Abstract][Full Text] [Related]
11. Clinical and economic benefits of ramipril: an Australian analysis of the HOPE study.
Smith MG; Neville AM; Middleton JC
Intern Med J; 2003; 33(9-10):414-9. PubMed ID: 14511193
[TBL] [Abstract][Full Text] [Related]
12. Patterns of persistence with antihypertensive medications in newly diagnosed hypertensive patients in Italy: a retrospective cohort study in primary care.
Mazzaglia G; Mantovani LG; Sturkenboom MC; Filippi A; Trifirò G; Cricelli C; Brignoli O; Caputi AP
J Hypertens; 2005 Nov; 23(11):2093-100. PubMed ID: 16208153
[TBL] [Abstract][Full Text] [Related]
13. Markers for cardiovascular and renal morbidity: expectations for an intervention programme in an Australian aboriginal community.
Hoy WE; McFarlane R; Pugsley DJ; Norman R; Mathews JD
Clin Exp Pharmacol Physiol; 1996 Aug; 23(8):S33-7. PubMed ID: 8886511
[TBL] [Abstract][Full Text] [Related]
14. Multinational economic evaluation of valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT).
Reed SD; Friedman JY; Velazquez EJ; Gnanasakthy A; Califf RM; Schulman KA
Am Heart J; 2004 Jul; 148(1):122-8. PubMed ID: 15215801
[TBL] [Abstract][Full Text] [Related]
15. Renal disease in Australian Aborigines.
Hoy W
Nephrol Dial Transplant; 2000 Sep; 15(9):1293-7. PubMed ID: 10978381
[No Abstract] [Full Text] [Related]
16. The multidimensional nature of renal disease: rates and associations of albuminuria in an Australian Aboriginal community.
Hoy WE; Mathews JD; McCredie DA; Pugsley DJ; Hayhurst BG; Rees M; Kile E; Walker KA; Wang Z
Kidney Int; 1998 Oct; 54(4):1296-304. PubMed ID: 9767547
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of hypertension therapy according to 2014 guidelines.
Moran AE; Odden MC; Thanataveerat A; Tzong KY; Rasmussen PW; Guzman D; Williams L; Bibbins-Domingo K; Coxson PG; Goldman L
N Engl J Med; 2015 Jan; 372(5):447-55. PubMed ID: 25629742
[TBL] [Abstract][Full Text] [Related]
18. Cost effectiveness of perindopril in reducing cardiovascular events in patients with stable coronary artery disease using data from the EUROPA study.
Briggs A; Mihaylova B; Sculpher M; Hall A; Wolstenholme J; Simoons M; Deckers J; Ferrari R; Remme WJ; Bertrand M; Fox K;
Heart; 2007 Sep; 93(9):1081-6. PubMed ID: 17135223
[TBL] [Abstract][Full Text] [Related]
19. Effect of a pharmacist-managed hypertension program on health system costs: an evaluation of the Study of Cardiovascular Risk Intervention by Pharmacists-Hypertension (SCRIP-HTN).
Houle SK; Chuck AW; McAlister FA; Tsuyuki RT
Pharmacotherapy; 2012 Jun; 32(6):527-37. PubMed ID: 22552863
[TBL] [Abstract][Full Text] [Related]
20. An economic analysis of captopril in the treatment of diabetic nephropathy. The Collaborative Study Group.
Rodby RA; Firth LM; Lewis EJ
Diabetes Care; 1996 Oct; 19(10):1051-61. PubMed ID: 8886549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
